Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Pro

Showing results (121-130 of 187) with videos related to

Pageof 19
Sort By:
British Journal of Haematology|June 28, 2013
Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomasFredrick Hagemeister, Maria Alma Rodriguez, Steven R Deitcher, et al.
Blood Advances|January 18, 2024
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimenReem Karmali, Carlos Galvez, Mehdi Hamadani, et al.
The Journal of Infectious Diseases|October 21, 2006
Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphomaAmar Safdar, M Alma Rodriguez, Luis E Fayad, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 30, 2015
A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell TransplantationSameh Gaballa, Neil Palmisiano, Onder Alpdogan, et al.
Leukemia & Lymphoma|November 4, 2020
Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphomaJonathan Pan, Sushil Ghimire, S Onder Alpdogan, et al.
British Journal of Haematology|April 2, 2015
Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomasFelipe Samaniego, Fredrick Hagemeister, Jorge E Romaguera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2004
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphomaNam H Dang, Fredrick B Hagemeister, Barbara Pro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapyBertrand Coiffier, Barbara Pro, H Miles Prince, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2026
Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell LymphomaNeha Mehta-Shah, Pier Luigi Zinzani, Eric D Jacobsen, et al.
British Journal of Haematology|January 4, 2014
Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study)Carlo Messina, Andrés J M Ferreri, Silvia Govi, et al.
Pageof 19

Showing results (121-130 of 187) with videos related to

Sort By:
Pageof 19
British Journal of Haematology|June 28, 2013
Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomasFredrick Hagemeister, Maria Alma Rodriguez, Steven R Deitcher, et al.
Blood Advances|January 18, 2024
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimenReem Karmali, Carlos Galvez, Mehdi Hamadani, et al.
The Journal of Infectious Diseases|October 21, 2006
Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphomaAmar Safdar, M Alma Rodriguez, Luis E Fayad, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 30, 2015
A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell TransplantationSameh Gaballa, Neil Palmisiano, Onder Alpdogan, et al.
Leukemia & Lymphoma|November 4, 2020
Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphomaJonathan Pan, Sushil Ghimire, S Onder Alpdogan, et al.
British Journal of Haematology|April 2, 2015
Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomasFelipe Samaniego, Fredrick Hagemeister, Jorge E Romaguera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2004
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphomaNam H Dang, Fredrick B Hagemeister, Barbara Pro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapyBertrand Coiffier, Barbara Pro, H Miles Prince, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2026
Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell LymphomaNeha Mehta-Shah, Pier Luigi Zinzani, Eric D Jacobsen, et al.
British Journal of Haematology|January 4, 2014
Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study)Carlo Messina, Andrés J M Ferreri, Silvia Govi, et al.
Pageof 19